Compare Novartis AG (NVS) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Uranium Energy Corp — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Uranium Energy Corp trades at $9.55 (market cap $4.65B). The key difference: Novartis AG is far larger — about 62.4× Uranium Energy Corp's market cap, and Novartis AG pays a 3.17% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals.
| NVS | UEC | |
|---|---|---|
Market Cap | $290.25B | $4.65B |
Sector | Health | Energy |
52-Week High | $168.62 | $20.14 |
52-Week Low | $113.50 | $8.00 |
Enterprise Value | $330.27B | $4.16B |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Uranium Energy Corp (UEC) trades at $9.40, up 1.29% today, amid bearish technical signals and challenging fundamentals. The stock shows negative profitability with a net income margin of -513.24% and has missed earnings estimates in two of the last three quarters. Recent news highlights operational pressures and strategic positioning in the uranium sector, with analyst sentiment remaining largely positive despite financial headwinds.
The outlook for UEC hinges on execution of its in-situ recovery ramp-up and uranium sales timing. Investment opportunity lies in its debt-free balance sheet and $794 million liquidity, but risks include persistent losses, high valuation multiples, and reliance on uranium price recovery. Wall Street maintains a buy-heavy consensus, suggesting long-term potential if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
